NCT05320796RecruitingPhase 4
The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass
The Bioavailability and Effect on Pouch pH of Esomeprazole as Tablets or in Solution After Laparoscopic Proximal RYGB for Morbid Obesity - an Investigator Blinded Pilot Study
Source: ClinicalTrials.gov · Last updated 9 Jun 2026
Brief summary (registry, in English)
The objective of this study is to investigate the effect of Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water) on acid production in the gastric pouch by measuring the intragastric pH and the serum concentration of esomeprazole.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 29 Dec 2021
- Start date
- 1 Nov 2023
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Prof Urs Zingg
- Diseases
- Obesity
- NCT number
- NCT05320796
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 50
- From 1 Nov 2023 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known intolerance or allergy for Esomeprazol
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
Other
- Contraindication for upper endoscopy
- Women who are pregnant or breast feeding Major hepatic dysfunction
Who the study is looking for
- Proximal Roux-en-Y gastric bypass with linear stapled anastomosis 12 months prior to the study investigation
- Routine administration of proton pump inhibitors for 6 months postoperatively
- No intake of proton pump inhibitors at least 4 weeks prior to study investigation
- No marginal ulcers in upper endoscopy prior to placement of wireless BRAVO™ pH monitoring capsule
- No symptoms related to gastro-esophageal reflux or marginal ulcers (i.e. epigastric pain, retrosternal burning, regurgitation)
- Informed consent as documented by signature
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Spital Limmattal Coordinator of this site? Confirm its status | Schlieren | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.